David Chen > Goodwin > Santa Monica, United States > Lawyer Profile
Goodwin Offices
520 Broadway Suite #500
Santa Monica
CA 90401
CALIFORNIA
United States
- Firm Profile
- Go to...
David Chen
Position
Partner
Career
David R. Chen is a life sciences and technology transactions lawyer based on the West Coast and in Asia. He is an expert on strategic and cross-border licensing, collaboration, and strategic partner transactions, technology-/data-driven transactions, and commercial transactions in the life sciences and technology sectors.
David represents life sciences companies of all sizes and stages, from emerging biotechs/med-techs to large multi-national pharmaceutical/medical tech companies. He spent 14+ years living and practicing in Asia, where he assisted foreign and local companies in transactions involving China, Japan, S. Korea, S.E. Asia, and worldwide territories. David’s life sciences expertise encompasses the entire life sciences value chain, from early-stage collaboration on drug discovery, in-licensing and out-licensing of pre-clinical and clinical-stage drug candidates, CMO, CRO, and CSO arrangements, supply and distribution arrangements, promotion and commercialization arrangements, pipeline optimization and divestiture transactions, and cross-industry digital health initiatives.
David also regularly advises technology, software, e-commerce, mobile app, mobile gaming, digital media, and data-driven companies on their strategic transactions, partnering arrangements, and investments, and regularly advises companies across a broad range of industries on China and Hong Kong privacy and data protection laws and compliance.
David is a California native, and is fluent in English and Mandarin Chinese.
Education
JD 2008 Boston University; MA International Relations 2009 Boston University; LLM Chinese Law 2008 Tsinghua University; BA Business Economics and Sociology 2002 University of California, Los Angeles
Lawyer Rankings
United States > Healthcare > Life sciences
With a raft of lawyers ‘whose experience is deeply rooted in the space,’ Goodwin is able to assist life sciences sector clients across the spectrum of related issues, ranging from multi-billion dollar acquisitions, to securing FDA approval for groundbreaking drugs, and obtaining patent protection for their products. 2023 saw extensive hiring at the partner level, with the October 2023 arrivals of licensing specialist David Chen in Santa Monica from Ropes & Gray LLP and capital markets expert Adam Johnson from Latham & Watkins LLP in New York underscoring the arrival in Philadelphia of a 10-strong team from Troutman Pepper in February. Mitchell Bloom leads the team alongside Kingsley Taft, with both assisting clients in securing VC funding and with eventual IPOs, with the latter also handling licensing agreements and the structuring of joint ventures; both are based in Boston. Also in Boston, Marishka DeToy and Robert Puopolo‘s practices center on capital markets transactions in the sector. The firm’s FDA regulatory experts are Steven Tjoe and Alexander Varond, both based in Washington DC and advising on medical devices and drug development processes.
United States > Intellectual property > Patents: prosecution (including re-examination and post-grant proceedings)
(Firms to watch)Goodwin‘s patent prosecution collective has been significantly bolstered with the arrivals of David Chen to Santa Monica in October 2023 from Ropes & Gray LLP and of Pittsburgh-based Alicia Palladino, Philadelphia’s Daniel Scolnick and Timothy Atkins from Troutman Pepper in February of the same year.
Lawyer Rankings
- Life sciences United States > Healthcare
- Firms to watch United States > Intellectual property > Patents: prosecution (including re-examination and post-grant proceedings)
Top Tier Firm Rankings
- Finance > Financial services regulation
- Industry focus > Cannabis
- Intellectual property > Patents: licensing
- M&A/corporate and commercial > Private equity buyouts: middle-market (Up to $500m)
- Real estate > Real estate investment trusts (REITs)
- Media, technology and telecoms > Technology transactions
- M&A/corporate and commercial > Venture capital and emerging companies
Firm Rankings
- Finance > Capital markets: equity offerings
- Labor and employment > ERISA litigation
- Finance > Fintech
- Healthcare > Life sciences
- Dispute resolution > M&A litigation: defense
- M&A/corporate and commercial > M&A: middle-market ($500m-999m)
- Real estate > Real estate
- Dispute resolution > Securities litigation: defense
- Intellectual property > Trade secrets (litigation and non-contentious matters)
- Finance > Capital markets: debt offerings
- International trade > CFIUS
- M&A/corporate and commercial > Corporate governance
- Media, technology and telecoms > Cyber law (including data privacy and data protection)
- Dispute resolution > E-discovery
- Labor and employment > Employee benefits, executive compensation and retirement plans: transactional
- Dispute resolution > Financial services litigation
- Antitrust > Merger control
- Intellectual property > Patents: litigation (full coverage)
- Investment fund formation and management > Private equity funds (including venture capital)
- Dispute resolution > Product liability, mass tort and class action - defense: consumer products (including tobacco)
- Tax > US taxes: non-contentious
- Labor and employment > Workplace and employment counseling
- International trade > Customs, export controls and economic sanctions
- Healthcare > Service providers
- Dispute resolution > Leading trial lawyers
- Dispute resolution > Leading trial lawyers
- Finance > Restructuring (including bankruptcy): corporate
- Dispute resolution > Appellate: courts of appeals / Appellate: supreme courts (states and federal)
- Finance > Commercial lending
- Dispute resolution > Corporate investigations and white-collar criminal defense
- Intellectual property > Patents: litigation (International Trade Commission)
- Intellectual property > Patents: prosecution (including re-examination and post-grant proceedings)
- M&A/corporate and commercial > Shareholder activism